Trial Profile
A randomized, open label, single center, phase IIa controlled trial to assess tolerability, safety and effect of treatment with deferasirox plus standard antiviral therapy versus standard antiviral therapy in chronic hepatitis C patients naive to treatment with interferon and/or ribavirin.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 Mar 2015
Price :
$35
*
At a glance
- Drugs Deferasirox (Primary) ; Peginterferon; Ribavirin
- Indications Hepatitis C
- Focus Adverse reactions
- 14 Jun 2011 New trial record